Drug Approval | June 17, 2024
Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
